跳至主要内容
临床试验/NCT02100917
NCT02100917已完成1 期

Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

Meiji Seika Pharma Co., Ltd.0 个研究点目标入组 70 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
70
主要终点
Maximum observed serum concentration (Cmax)

研究概览

简要总结

This study is a randomized Trastuzumab-controlled double-blind parallel-group study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 39 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy Japanese male adults
  • Body Mass Index (BMI) between 17.6 and 26.4 kg/m² at the time of screening BMI = Body Weight (kg)/[Height (m)]²
  • The individual who freely consents to participate after receiving a detailed explanation of the clinical study and completely understanding thereof, and who has capacity to follow precautions and provide written consent.

排除标准

  • History of hypersensitivity to components of Trastuzumab or diphenhydramine or any other drug
  • Use of any ethical drug within 2 weeks before investigational product administration or any over-the-counter drug within 1 week before investigational product administration that would affect study participation in the opinion of the investigator or subinvestigators (except for diphenhydramine, which will be used concomitantly in the present clinical trial and any drug applied locally and having no systemic actions)
  • History of allergic symptoms such as bronchial asthma and urticaria that would affect study participation in the opinion of the investigator or subinvestigators
  • History of cardiac disorders, hypertension, coronary artery disease (e.g., myocardial infarction, angina), and/or vascular disorder; ongoing palpitations, shortness of breath, and/or tachycardia

研究组 & 干预措施

DMB-3111

Experimental

6 mg/kg is once given in intravenous drip infusion taking 90 min

干预措施: DMB-3111 (Drug)

trastuzumab

Active Comparator

6 mg/kg is once given in intravenous drip infusion taking 90 min

干预措施: trastuzumab (Drug)

结局指标

主要结局

Maximum observed serum concentration (Cmax)

时间窗: Day1-71

Area Under the Concentration-Time (AUC)

时间窗: Day1-71

次要结局

  • Area under the concentration-time curve (AUC) from 0 to time of the last measurable concentration(Day1-71)
  • Mean residence time (MRT) from 0 to infinity(Day1-71)
  • Area under the concentration-time curve (AUC) from 0 to infinity(Day1-71)
  • Time to reach the peak concentration (tmax)(Day1-71)
  • Mean residence time (MRT) from 0 to final sampling time point(Day1-71)
  • elimination rate constant (kel)(Day1-71)
  • Incidence of adverse events(Day1-71)
  • Elimination half life (t1/2)(Day1-71)
  • Clearance (CL)(Day1-71)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验